December 18, 2013

Subject: Recall of METHOTREXATE SODIUM INJECTION 25 mg/mL (2mL) DIN 02099705 – Distributed by Teva Canada Limited (formerly Novopharm Limited) Lots 12J30KK, 12J30KH, 12J30KB due to possible cracks in glass container

Teva Canada Limited, in consultation with Health Canada, is initiating a voluntary recall of 3 lots (listed above) of METHOTREXATE SODIUM INJECTION 25mg/mL (2mL) due to the possibility of cracks in the glass containers. This medication may be used in the treatment of cancer, psoriasis and arthritis related conditions.

Although this Product is used in hospitals and in cancer clinics, Health Canada has advised that there may be instances where it could be used by doctors in their office or by a patient in their own home.